Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/20/2023 | $19.00 | Neutral | Goldman |
| 7/18/2023 | $44.00 | Outperform | William Blair |
| 5/18/2023 | Buy | Guggenheim | |
| 8/1/2022 | $40.00 | Overweight | Barclays |
| 12/21/2021 | $40.00 | Buy | HC Wainwright & Co. |
| 11/23/2021 | $55.00 | Outperform | Oppenheimer |
| 10/8/2021 | $50.00 → $65.00 | Strong Buy | Raymond James |
| 6/29/2021 | $39.00 → $50.00 | Strong Buy | Raymond James |
HC Wainwright & Co. analyst Oren Livnat maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and raises the price target from $57 to $61.
Gainers Tevogen Bio Holdings (NASDAQ:TVGN) stock rose 55.4% to $1.53 during Monday's pre-market session. The market value of their outstanding shares is at $251.8 million. MiNK Therapeutics (NASDAQ:INKT) stock increased by 31.09% to $1.18. The company's market cap stands at $40.9 million. Dynatronics (NASDAQ:DYNT) stock increased by 21.69% to $0.57. The company's market cap stands at $2.8 million. As per the press release, Q3 earnings came out 2 days ago. Tarsus Pharmaceuticals (NASDAQ:TARS) shares moved upwards by 18.08% to $43.69. The market value of their outstanding shares is at $1.6 billion. As per the news, the Q1 earnings report came out 3 days ago. CareCloud (NASDAQ:CCLD) shares
Barclays analyst Balaji Prasad maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Overweight and raises the price target from $50 to $60.
IRVINE, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), whose mission is to address unmet medical needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the appointment of Elizabeth Yeu, M.D., as Chief Medical Officer, effective November 4, 2024. A distinguished ophthalmologist with more than two decades of clinical experience and leadership, Dr. Yeu has served as Tarsus' Chief Medical Advisor since 2020 and as a Board member since 2021. In this new role, she will be responsible for leading the strategy, direction and execution of the Company's new Medical Organization compris
IRVINE, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the appointment of Jeff Farrow as Chief Financial Officer and Chief Strategy Officer, effective immediately. Mr. Farrow succeeds Leo Greenstein who served as CFO since 2020 and will be leaving Tarsus to pursue other professional interests. Mr. Farrow is a seasoned finance and corporate strategy executive with more than two decades of experience successfully leading teams in the life science industry, including several publicly tra
Mr. Morrison brings over 40 years of financial and operational expertise in life sciences IRVINE, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), whose mission is to address unmet patient needs, starting with eye care, through the application of proven science and new technology, today announced the appointment of Scott Morrison as Board Member and Audit Committee Chair. Mr. Morrison is a seasoned accounting and finance professional in the life sciences industry. He brings extensive expertise in corporate financing, pharmaceutical company operations, business development, and corporate governance. "We are pleased that Scott is joining the Board and s
IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Wednesday, November 13, 2024 to report its third quarter 2024 financial results and provide a corporate update. Participants may access the webcast here. A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for approximately 90 days. About Tarsus Pharmaceuticals, Inc.Tarsus Pharmaceutic
IRVINE, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), whose mission is to address unmet medical needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the appointment of Elizabeth Yeu, M.D., as Chief Medical Officer, effective November 4, 2024. A distinguished ophthalmologist with more than two decades of clinical experience and leadership, Dr. Yeu has served as Tarsus' Chief Medical Advisor since 2020 and as a Board member since 2021. In this new role, she will be responsible for leading the strategy, direction and execution of the Company's new Medical Organization compris
Campaign showcases root cause of Demodex blepharitis through creative representation of mischief-causing mites on patients' eyelids Demodex blepharitis is a significant eyelid disease that impacts approximately 25 million people in the U.S. – or 1 out of every 12 adults Media accompanying this announcement is available by clicking on this link IRVINE, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced the launch of a new direct-to-consumer TV campaign for XDEMVY® (lotilaner ophth
8-K - Tarsus Pharmaceuticals, Inc. (0001819790) (Filer)
10-Q - Tarsus Pharmaceuticals, Inc. (0001819790) (Filer)
8-K - Tarsus Pharmaceuticals, Inc. (0001819790) (Filer)
Goldman initiated coverage of Tarsus Pharmaceuticals with a rating of Neutral and set a new price target of $19.00
William Blair initiated coverage of Tarsus Pharmaceuticals with a rating of Outperform and set a new price target of $44.00
Guggenheim initiated coverage of Tarsus Pharmaceuticals with a rating of Buy
4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)
IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Wednesday, November 13, 2024 to report its third quarter 2024 financial results and provide a corporate update. Participants may access the webcast here. A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for approximately 90 days. About Tarsus Pharmaceuticals, Inc.Tarsus Pharmaceutic
Generated $40.8 million in XDEMVY® net product sales in the second quarter and $65.5 million year-to-date Delivered more than 37,000 bottles of XDEMVY to patients in the second quarter Delivered an exceptional gross-to-net discount of 44% reflecting strong payer coverage including commercial and Medicare payers Expanded sales force remains on-track to be fully deployed by the end of the third quarter 2024 Management to host conference call today, August 8, 2024, at 1:30 p.m. P.T. / 4:30 p.m. E.T. IRVINE, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolut
IRVINE, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Thursday, August 8, 2024 to report its second quarter 2024 financial results and provide a corporate update. Participants may access the webcast here. A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for approximately 90 days. About Tarsus Pharmaceuticals, Inc.Tarsus Pharmaceuticals
Submission status for TARSUS PHARMACEUTICALS, INC.'s drug XDEMVY (ORIG-1) with active ingredient LOTILANER has changed to 'Approval' on 07/24/2023. Application Category: NDA, Application Number: 217603, Application Classification: Type 1 - New Molecular Entity
Submission status for TARSUS PHARMACEUTICALS, INC.'s drug (ORIG-1) with active ingredient has changed to 'Approval' on 07/24/2023. Application Category: NDA, Application Number: 217603, Application Classification: Type 1 - New Molecular Entity
Submission status for TARSUS PHARMACEUTICALS, INC's drug (SUPPL-1) with active ingredient has changed to 'Approval' on 07/24/2023. Application Category: NDA, Application Number: 217603, Application Classification: Type 1 - New Molecular Entity
SC 13G/A - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)
SC 13G/A - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)
SC 13G/A - Tarsus Pharmaceuticals, Inc. (0001819790) (Subject)
4 - Tarsus Pharmaceuticals, Inc. (0001819790) (Issuer)